Biotech Acquisition Company (BIOTU)

The chart shows the growth of $10,000 invested in Biotech Acquisition Company in Sep 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $9,835 for a total return of roughly -1.65%. All prices are adjusted for splits and dividends.

Biotech Acquisition Company had a return of 1.10% year-to-date (YTD) and 1.65% in the last 12 months. Over the past 10 years, Biotech Acquisition Company had an annualized return of -0.81%, while the S&P 500 had an annualized return of 3.01%, indicating that Biotech Acquisition Company did not perform as well as the benchmark.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Biotech Acquisition Company Sharpe ratio is 0.05. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Biotech Acquisition Company. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Biotech Acquisition Company is 16.36%, recorded on May 26, 2022. It took 171 trading sessions for the portfolio to recover.

Current Biotech Acquisition Company volatility is 62.39%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.